An open, multicentre phase II trial assessing the objective response rate after combination of Arimidex 1mg per os per day and Zoladex 3.6 mg sub cutaneously monthly as first treatment for premenopausal receptor positive advanced or metastatic breast cancer
Study identifier:D5390000000
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open, multicentre phase II trial assessing the objective response rate after combination of Arimidex 1mg per os per day and Zoladex 3.6 mg sub cutaneously monthly as first treatment for premenopausal receptor positive advanced or metastatic breast cancer
Medical condition
Oncology
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Dec 2001
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
-
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
